In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price target of $3.00. The company’s shares opened today at $0.85.
According to TipRanks, McCarthy is an analyst with an average return of -38.2% and a 14.81% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Daré Bioscience, and Capricor Therapeutics.
Currently, the analyst consensus on Matinas BioPharma is a Strong Buy with an average price target of $3.00, implying a 252.94% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $1.61 and a one-year low of $0.49. Currently, Matinas BioPharma has an average volume of 400.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company’s proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.
Read More on MTNB:
